Alexander M M Eggermont

Summary

Affiliation: Erasmus MC
Country: The Netherlands

Publications

  1. ncbi Does adjuvant systemic therapy with interferon-alpha for stage II-III melanoma prolong survival?
    Alexander M M Eggermont
    Department of Surgical Oncology, Erasmus University Medical Center Rotterdam, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Am J Clin Dermatol 4:531-6. 2003
  2. ncbi Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial
    Alexander M M Eggermont
    Department of Surgical Oncology, Erasmus University Medical Centre Daniel den Hoed Cancer Centre, 3008 AE Rotterdam, Netherlands
    Lancet 366:1189-96. 2005
  3. ncbi Current status of interferon-alpha in the treatment of melanoma
    Alexander M M Eggermont
    Department of Surgical Oncology, Erasmus University Medical Center--Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Cancer Chemother Biol Response Modif 22:729-37. 2005
  4. ncbi Randomized adjuvant therapy trials in melanoma: surgical and systemic
    Alexander M M Eggermont
    Department of Surgical Oncology, Erasmus University Medical Center Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Semin Oncol 34:509-15. 2007
  5. ncbi Current uses of isolated limb perfusion in the clinic and a model system for new strategies
    Alexander M M Eggermont
    Department of Surgical Oncology, Erasmus University Medical Center Rotterdam, Daniel den Hoed Cancer Center, Rotterdam, Netherlands
    Lancet Oncol 4:429-37. 2003
  6. ncbi Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial
    Alexander M M Eggermont
    Erasmus University Medical Center, Rotterdam, Netherlands
    Lancet 372:117-26. 2008
  7. ncbi Management of melanoma: a European perspective
    Alexander M M Eggermont
    Department of Surgical Oncology, Erasmus University Medical Center Daniel den Hoed Cancer Center, 301 Groene Hilledijk, 3075 EA Rotterdam, The Netherlands
    Surg Oncol Clin N Am 17:635-48, x. 2008
  8. ncbi Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?
    Alexander M M Eggermont
    Department of Surgical Oncology, Erasmus University Medical Center, Groene Hilledijk 301, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Eur J Cancer 40:1825-36. 2004
  9. ncbi Randomized trials in melanoma: an update
    Alexander M M Eggermont
    Erasmus Medical Center, Daniel den Hoed Cancer Center, 301 Groene Hilledijk, EA 3075, Rotterdam, The Netherlands
    Surg Oncol Clin N Am 15:439-51. 2006
  10. ncbi Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies--EORTC 18991
    Marna G Bouwhuis
    Department of Surgery, Division Surgical Oncology, Erasmus University Medical Center Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    J Clin Oncol 28:2460-6. 2010

Detail Information

Publications103 found, 100 shown here

  1. ncbi Does adjuvant systemic therapy with interferon-alpha for stage II-III melanoma prolong survival?
    Alexander M M Eggermont
    Department of Surgical Oncology, Erasmus University Medical Center Rotterdam, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Am J Clin Dermatol 4:531-6. 2003
    ..For now the role of interferon-alpha still remains to be determined and its use should be restricted to the setting of clinical trials...
  2. ncbi Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial
    Alexander M M Eggermont
    Department of Surgical Oncology, Erasmus University Medical Centre Daniel den Hoed Cancer Centre, 3008 AE Rotterdam, Netherlands
    Lancet 366:1189-96. 2005
    ..Our aim was, therefore, to assess the effect of two regimens of interferon of intermediate dose versus observation alone on distant metastasis-free interval (DMFI) and overall survival in such patients...
  3. ncbi Current status of interferon-alpha in the treatment of melanoma
    Alexander M M Eggermont
    Department of Surgical Oncology, Erasmus University Medical Center--Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Cancer Chemother Biol Response Modif 22:729-37. 2005
  4. ncbi Randomized adjuvant therapy trials in melanoma: surgical and systemic
    Alexander M M Eggermont
    Department of Surgical Oncology, Erasmus University Medical Center Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Semin Oncol 34:509-15. 2007
    ..The population of patients that can benefit from IFN needs to be better defined by identifying new biomarkers by genomic and proteomic studies, which are ongoing...
  5. ncbi Current uses of isolated limb perfusion in the clinic and a model system for new strategies
    Alexander M M Eggermont
    Department of Surgical Oncology, Erasmus University Medical Center Rotterdam, Daniel den Hoed Cancer Center, Rotterdam, Netherlands
    Lancet Oncol 4:429-37. 2003
    ..Moreover, isolated limb perfusion is an effective modality for gene therapy mediated by an adenoviral vector. Various clinical phase I-II studies can be expected in the next few years...
  6. ncbi Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial
    Alexander M M Eggermont
    Erasmus University Medical Center, Rotterdam, Netherlands
    Lancet 372:117-26. 2008
    ..Any benefit of adjuvant interferon alfa-2b for melanoma could depend on dose and duration of treatment. Our aim was to determine whether pegylated interferon alfa-2b can facilitate prolonged exposure while maintaining tolerability...
  7. ncbi Management of melanoma: a European perspective
    Alexander M M Eggermont
    Department of Surgical Oncology, Erasmus University Medical Center Daniel den Hoed Cancer Center, 301 Groene Hilledijk, 3075 EA Rotterdam, The Netherlands
    Surg Oncol Clin N Am 17:635-48, x. 2008
    ..Interferon has a consistent effect on relapse-free survival, although it does not have a significant benefit for overall survival...
  8. ncbi Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?
    Alexander M M Eggermont
    Department of Surgical Oncology, Erasmus University Medical Center, Groene Hilledijk 301, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Eur J Cancer 40:1825-36. 2004
    ..Single-administration dacarbazine (850-1000 mg/m2), once every 3 weeks, is currently the standard reference therapy in patients with advanced melanoma. New effective therapies are urgently needed for this treatment-refractory disease...
  9. ncbi Randomized trials in melanoma: an update
    Alexander M M Eggermont
    Erasmus Medical Center, Daniel den Hoed Cancer Center, 301 Groene Hilledijk, EA 3075, Rotterdam, The Netherlands
    Surg Oncol Clin N Am 15:439-51. 2006
    ..Efforts must be made to improve understanding of the biology of malignant melanoma. Too many phase III trials have been conducted with a poor understanding of the mechanism of action of the involved drugs...
  10. ncbi Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies--EORTC 18991
    Marna G Bouwhuis
    Department of Surgery, Division Surgical Oncology, Erasmus University Medical Center Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    J Clin Oncol 28:2460-6. 2010
    ..We evaluated the prognostic significance of autoantibodies in the European Organisation for Research and Treatment of Cancer 18991 trial, comparing long-term administration of pegylated IFN (PEG-IFN) with observation...
  11. ncbi Decreased response rates by the combination of histamine and IL-2 in melphalan-based isolated limb perfusion
    Flavia Brunstein
    Department of Surgical Oncology, Erasmus MC, Laboratory of Experimental Surgical Oncology, Daniel den Hoed Cancer Centre, Room Ee 0175, P O Box 1738, 3000 DR, Rotterdam, The Netherlands
    Cancer Immunol Immunother 56:573-80. 2007
    ..8-fold), or IL-2 only (3.5-fold) combined to melphalan. In vitro there was no synergy between the drugs. In conclusion there was a negative synergistic effect between IL-2 and Hi in the regional setting...
  12. ncbi Early destruction of tumor vasculature in tumor necrosis factor-alpha-based isolated limb perfusion is responsible for tumor response
    Saske Hoving
    Department of Surgical Oncology, Erasmus MC-Daniel den Hoed Cancer Center, 3000 DR Rotterdam, The Netherlands
    Anticancer Drugs 17:949-59. 2006
    ..g. interstitial fluid pressure and pH), we speculate that the tumor vascular changes, and concurrent hemorrhage and drug accumulation are the key explanations for the observed synergistic anti-tumor response...
  13. ncbi Isolated hypoxic hepatic perfusion with retrograde outflow in patients with irresectable liver metastases; a new simplified technique in isolated hepatic perfusion
    Cornelis Verhoef
    Department of Surgical Oncology, Erasmus University Medical Centre Daniel den Hoed Cancer Centre, PO Box 5201, 3008 AE, Rotterdam, The Netherlands
    Ann Surg Oncol 15:1367-74. 2008
    ..Major drawbacks are magnitude and costs of the procedure. We developed an isolated hypoxic hepatic perfusion (IHHP) with retrograde outflow without the need for a heart-lung machine...
  14. ncbi Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure
    Dirk J Grunhagen
    Department of Surgical Oncology, Erasmus MC Daniel den Hoed Cancer Center, PO Box 5201, 3008 AE, Rotterdam, The Netherlands
    Ann Surg Oncol 12:609-15. 2005
    ..Recurrences after ILP, however, occur in approximately 50% of patients and are a challenge for further treatment. The efficacy of repeat ILPs to prolong local control in this patient category is evaluated in this article...
  15. ncbi The palliative value of tumor necrosis factor alpha-based isolated limb perfusion in patients with metastatic sarcoma and melanoma
    Dirk J Grunhagen
    Department of Surgical Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Cancer 106:156-62. 2006
    ..CONCLUSIONS: TNF-based ILP is an excellent procedure that provided tumor control and limb salvage for the short survival of patients with metastasized, very bulky, limb-threatening tumors of the extremity...
  16. ncbi Technology insight: Utility of TNF-alpha-based isolated limb perfusion to avoid amputation of irresectable tumors of the extremities
    Dirk J Grunhagen
    Department of Surgical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Nat Clin Pract Oncol 3:94-103. 2006
    ..It represents an important example of combination therapy that modulates the tumor vasculature and should be offered in high-volume tertiary referral centers...
  17. ncbi Synergistic antitumor response of interleukin 2 with melphalan in isolated limb perfusion in soft tissue sarcoma-bearing rats
    Saske Hoving
    Department of Surgical Oncology, Erasmus MC, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Cancer Res 65:4300-8. 2005
    ..The results in our study indicate that the novel combination of IL-2 and melphalan in ILP has synergistic antitumor activity and may be an alternative for ILP with TNF and melphalan...
  18. ncbi Nitric oxide production and monoamine oxidase activity in cancer patients during interferon-alpha therapy
    Durk Fekkes
    Department of Neuroscience, Erasmus MC, Rotterdam, The Netherlands
    Amino Acids 37:703-8. 2009
    ....
  19. ncbi Interferon-alpha in oncology patients: fewer psychiatric side effects than anticipated
    Marjolein Bannink
    Dept of Psychiatry, Erasmus Medical Center, Rotterdam, The Netherlands
    Psychosomatics 49:56-63. 2008
    ..The results of this study indicate that IFN-alpha treatment is not suitable as a study model for depression in general...
  20. ncbi Prognostic factors after cervical lymph node dissection for cutaneous melanoma metastases
    Dirk J Grunhagen
    Department of Surgical Oncology, Erasmus MC Daniel den Hoed Cancer Centre, Rotterdam, The Netherlands
    Melanoma Res 15:179-84. 2005
    ..001). Selective CLND is the recommended procedure for patients with cervical metastases of cutaneous melanoma. The number of positive lymph nodes significantly affects the outcome of the patients...
  21. ncbi Outcome of microscopic incomplete resection (R1) of colorectal liver metastases in the era of neoadjuvant chemotherapy
    Ninos Ayez
    Division of Surgical Oncology, Erasmus MC, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Ann Surg Oncol 19:1618-27. 2012
    ....
  22. ncbi Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma
    Dirk J Grunhagen
    Department of Surgical Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Cancer 106:1776-84. 2006
    ..CONCLUSION: TNF+M-based ILP can provide limb salvage in a significant percentage of patients with locally advanced STS and has therefore gained a permanent place in the multimodality treatment of STS...
  23. ncbi Tumor necrosis factor alpha mediates homogeneous distribution of liposomes in murine melanoma that contributes to a better tumor response
    Ann L B Seynhaeve
    Department of Surgical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Cancer Res 67:9455-62. 2007
    ..We conclude that delivery of nanoparticulate drug formulations to solid tumor benefits from augmenting the vascular leakage through vascular manipulation with vasoactive drugs like TNF...
  24. ncbi Pegylated interferon-alpha2b treatment in melanoma patients: influence on amino acids, 5-hydroxyindolacetic acid and pteridine plasma concentrations
    Arthur R Van Gool
    Department of Psychiatry, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Anticancer Drugs 15:587-91. 2004
    ....
  25. ncbi Neurotoxic and neuroprotective metabolites of kynurenine in patients with renal cell carcinoma treated with interferon-alpha: course and relationship with psychiatric status
    Arthur R Van Gool
    Department of Psychiatry, Erasmus MC, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Psychiatry Clin Neurosci 62:597-602. 2008
    ..In contrast, other catabolites of KYN, such as kynurenic acid (KA), are thought to have neuroprotective properties...
  26. ncbi One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases
    Dirk J Grunhagen
    Department of Surgical Oncology, Daniel den Hoed Cancer Center, PO Box 5201 3008, Rotterdam, Netherlands
    Ann Surg 240:939-47; discussion 947-8. 2004
    ..The aim of this study is to describe the experience with 100 TNF-based ILP for locally advanced melanoma and to determine prognostic factors for response, time to local progression, and survival...
  27. ncbi Tumor necrosis factor-mediated interactions between inflammatory response and tumor vascular bed
    Timo L M ten Hagen
    Department of Surgical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Immunol Rev 222:299-315. 2008
    ..Understanding the mechanism of TNF and agents with comparable action on solid tumors is an important focus to further develop combination immunotherapy strategies...
  28. ncbi Value of intraoperative radiotherapy in locally advanced rectal cancer
    Floris T J Ferenschild
    Department of Surgical Oncology, Erasmus MC-Daniel den Hoed Cancer Center, 3008 AE Rotterdam, The Netherlands
    Dis Colon Rectum 49:1257-65. 2006
    ..Addition of intraoperative radiotherapy for patients with a narrow or microscopic incomplete resection seems to overrule the unfavorable prognostic histologic finding...
  29. ncbi Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas
    Jan P Deroose
    Daniel den Hoed Cancer Center, Erasmus MC, Rotterdam, The Netherlands
    J Clin Oncol 29:4036-44. 2011
    ..This study reports the long-term results of 231 TM-ILPs for locally advanced extremity STS...
  30. ncbi Addition of low-dose tumor necrosis factor-alpha to systemic treatment with STEALTH liposomal doxorubicin (Doxil) improved anti-tumor activity in osteosarcoma-bearing rats
    Saske Hoving
    Department of Surgical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Anticancer Drugs 16:667-74. 2005
    ..In conclusion, combination therapy of Doxil and low-dose TNF seems attractive for the treatment of highly vascularized tumors, but also of intermediate vascularized tumors like the osteosarcoma...
  31. ncbi Intratumoural expression of TNF-R1 and EMAP-II in relation to response of patients treated with TNF-based isolated limb perfusion
    Remco van Horssen
    Department of Surgical Oncology, Laboratory for Experimental Surgical Oncology, Erasmus MC Daniel den Hoed Cancer Centre, Rotterdam, The Netherlands
    Int J Cancer 119:1481-90. 2006
    ..Analysis of EMAP-II expression in melanoma biopsies should be implemented in the ILP procedure...
  32. ncbi Reirradiation, surgery and IORT for recurrent rectal cancer in previously irradiated patients
    Maarten Vermaas
    Department of Surgical Oncology, Erasmus MC Daniel den Hoed Cancer Centre, Rotterdam, The Netherlands
    Radiother Oncol 87:357-60. 2008
    ..This treatment was related with high morbidity, a short pain-free survival (5 months) and poor local control (27% after 3 years), although some patients have long-term distant control and survival...
  33. ncbi Isolated limb perfusion with tumor necrosis factor and melphalan prevents amputation in patients with multiple sarcomas in arm or leg
    Dirk J Grunhagen
    Department of Surgical Oncology, Erasmus MC Daniel den Hoed Cancer Center, 301 Groene Hilledijk, 3075 EA Rotterdam, The Netherlands
    Ann Surg Oncol 12:473-9. 2005
    ..To avoid amputations, isolated limb perfusion (ILP) with tumor necrosis factor and melphalan is an attractive treatment option for patients with multiple extremity sarcomas...
  34. ncbi Isolated limb perfusion with TNF-alpha and melphalan for distal parts of the limb in soft tissue sarcoma patients
    Jan P Deroose
    Division of Surgical Oncology, Daniel den Hoed Erasmus MC, Rotterdam, The Netherlands
    J Surg Oncol 105:563-9. 2012
    ..Tumor necrosis factor-alpha (TNF) and melphalan-based isolated limb perfusion (TM-ILP) is effective in locally advanced STS of the extremities. We report the results of TM-ILP for STS in the most distal parts of the limb...
  35. ncbi Gender differences in melanoma survival: female patients have a decreased risk of metastasis
    Arjen Joosse
    Department of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands
    J Invest Dermatol 131:719-26. 2011
    ..Localized melanomas in women had a lower propensity to metastasize, resulting in a better survival when compared with men, even after first disease progression. These results suggest differences in tumor-host interaction across gender...
  36. ncbi Synergistic antitumor activity of histamine plus melphalan in isolated limb perfusion: preclinical studies
    Flavia Brunstein
    Department of Surgical Oncology, Erasmus MC, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    J Natl Cancer Inst 96:1603-10. 2004
    ..These results warrant further evaluation in the clinical ILP setting and, importantly, in organ perfusion...
  37. ncbi Melanoma and immunotherapy
    Alexander M M Eggermont
    Department of Surgical Oncology, Erasmus University MC Daniel den Hoed Cancer Center, 301 Groene Hilledijk, 3075 EA Rotterdam, The Netherlands
    Hematol Oncol Clin North Am 23:547-64, ix-x. 2009
    ..Immunotherapies are developed for melanoma patients in stage IV who have distant metastases and in stage II to III patients in the adjuvant micrometastatic setting, where only a fraction of patients have widespread (microscopic) disease...
  38. ncbi Isolated limb perfusion with melphalan and TNF-alpha in the treatment of extremity sarcoma
    Cornelis Verhoef
    Department of Surgical Oncology, ErasmusMC Daniel den Hoed Cancer Center, 310 Groene Hilledijk, 3075 EA, Rotterdam, The Netherlands
    Curr Treat Options Oncol 8:417-27. 2007
    ..TNF-alpha-based ILP is a well-established treatment to avoid amputations. It represents an important example of tumor vascularity-modulating combination therapy and should be offered in large volume tertiary referral centers...
  39. ncbi Superior outcome of women with stage I/II cutaneous melanoma: pooled analysis of four European Organisation for Research and Treatment of Cancer phase III trials
    Arjen Joosse
    Department of Public Health, Erasmus University Medical Center, PO Box 2040 3000 CA, Rotterdam, The Netherlands
    J Clin Oncol 30:2240-7. 2012
    ....
  40. ncbi Outcome after therapeutic lymph node dissection in patients with unknown primary melanoma site
    Sebastiaan P Prens
    Erasmus University Medical Center, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Ann Surg Oncol 18:3586-92. 2011
    ..Disease-free (DFS) and overall survival (OS) time of MUP patients were analyzed and compared to patients undergoing a TLND for known primary melanomas (MKP)...
  41. ncbi Serum concentrations of pegylated interferon alpha-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon alpha-2b in a randomized phase III trial (EORTC 18991)
    Alexander M M Eggermont
    Department of Surgical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, 310 Groene Hilledijk, 3075 EA, Rotterdam, The Netherlands
    Cancer Chemother Pharmacol 65:671-7. 2010
    ..Serum concentrations were analyzed to determine exposure to Peg-IFN alpha-2b...
  42. ncbi Platelet MAO activity during treatment with pegylated interferon-alfa in melanoma patients
    Marjolein Bannink
    Department of Psychiatry, Erasmus MC Daniel den Hoed Cancer Center, P O Box 5201, 3008 AE Rotterdam, The Netherlands
    Prog Neuropsychopharmacol Biol Psychiatry 29:109-14. 2005
    ..In that case, increased platelet MAO activity reflects an increased number of mitochondria per platelet...
  43. ncbi Angiogenesis: a prognostic determinant in pancreatic cancer?
    Jill A van der Zee
    Laboratory of Experimental Surgical Oncology, Section of Surgical Oncology, Department of Surgery, Erasmus Medical Center, s Gravendijkwal 230, Rotterdam, The Netherlands
    Eur J Cancer 47:2576-84. 2011
    ..In conclusion, angiogenesis is higher in periampullary cancer and although associated with nodal involvement in pancreatic head cancer, pancreatic cancer prognosis seems indeed angiogenesis independent...
  44. ncbi The "liver-first approach" for patients with locally advanced rectal cancer and synchronous liver metastases
    Cornelis Verhoef
    Department of Surgical Oncology, Erasmus University MC, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Dis Colon Rectum 52:23-30. 2009
    ..This study was designed to investigate the outcome of "the liver-first" approach in patients with locally advanced rectal cancer and synchronous liver metastases...
  45. ncbi Radiotherapy for soft tissue sarcomas after isolated limb perfusion and surgical resection: essential for local control in all patients?
    Jan P Deroose
    Division of Surgical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Ann Surg Oncol 18:321-7. 2011
    ..Isolated limb perfusion (ILP) with tumor necrosis factor alpha (TNF-α) and melphalan can achieve regression of the tumor, facilitating limb-saving resection. RTx improves local control but may lead to increased morbidity...
  46. ncbi Effect of bevacizumab added preoperatively to oxaliplatin on liver injury and complications after resection of colorectal liver metastases
    Anne E M van der Pool
    Division of Surgical Oncology, Erasmus University MC, Daniel den Hoed Cancer Centre, Rotterdam, The Netherlands
    J Surg Oncol 106:892-7. 2012
    ..To ascertain whether adding bevacizumab, a monoclonal antibody against VEGF, to oxaliplatin-based CTx has an influence on liver injury and postoperative complications...
  47. ncbi Interferon-alpha influences tryptophan metabolism without inducing psychiatric side effects
    Marjolein Bannink
    Department of Psychiatry, Erasmus Medical Center, Rotterdam, The Netherlands
    Neuropsychobiology 55:225-31. 2007
    ..The alterations in tryptophan metabolism might underlie the psychiatric side effects during treatment with IFN-alpha...
  48. ncbi Sentinel lymph-node false positivity in melanoma
    Alexander C J van Akkooi
    Department of Surgical Oncology, Erasmus University MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Nat Clin Pract Oncol 5:E2. 2008
  49. ncbi Effect of low-dose tumor necrosis factor-alpha in combination with STEALTH liposomal cisplatin (SPI-077) on soft-tissue- and osteosarcoma-bearing rats
    Saske Hoving
    Department of Surgical Oncology, Erasmus MC, Rotterdam, The Netherlands
    Anticancer Res 25:743-50. 2005
    ....
  50. ncbi TNF-based isolated limb perfusion: a decade of experience with antivascular therapy in the management of locally advanced extremity soft tissue sarcomas
    Dirk J Grunhagen
    Dept of Surgical Oncology, Erasmus University Medical Centre Daniel den Hoed Cancer Centre, Rotterdam, The Netherlands
    Cancer Treat Res 120:65-79. 2004
  51. ncbi TNF and manipulation of the tumor cell-stromal interface: "ways to make chemotherapy effective"
    Ann L B Seynhaeve
    Department of Surgical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Front Biosci 13:3034-45. 2008
    ..In this dual approach, TNF enhances intratumoral accumulation of the chemotherapeutic drug resulting in an impressive tumor response...
  52. ncbi Synergistic antitumor effects of histamine plus melphalan in isolated hepatic perfusion for liver metastases
    Flavia Brunstein
    Department of Surgical Oncology, Erasmus MC, Daniel den Hoed Cancer Centre, Rotterdam, The Netherlands
    Ann Surg Oncol 14:795-801. 2007
    ..Because of its vasoactive properties, histamine (Hi) is an alternative to TNF. In this article we evaluate its potential synergistic effect in M-IHP, improving response rates...
  53. ncbi European approach to adjuvant treatment of intermediate- and high-risk malignant melanoma
    Alexander M M Eggermont
    Department of Surgical Oncology, Erasmus University Medical Center-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Semin Oncol 29:382-8. 2002
    ..Less toxic lower-dose maintenance IFN regimens, antiangiogenic agents, and vaccine therapies are currently being explored...
  54. ncbi Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria
    Augustinus P T van der Ploeg
    Erasmus University Medical Center Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    J Clin Oncol 29:2206-14. 2011
    ..These factors reflect biologic behavior and may separate out patients who may or may not need additional locoregional and/or systemic therapy...
  55. ncbi Tumor necrosis factor-based isolated limb perfusion for soft tissue sarcoma and melanoma: ten years of successful antivascular therapy
    Alexander M M Eggermont
    Department of Surgical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, 301 Groene Hilledijk, 3075 EA Rotterdam, Netherlands
    Curr Oncol Rep 5:79-80. 2003
  56. ncbi 20 years experience of TNF-based isolated limb perfusion for in-transit melanoma metastases: TNF dose matters
    Jan P Deroose
    Department of Surgical Oncology, ErasmusMC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Ann Surg Oncol 19:627-35. 2012
    ..This study reports on a 20 years experience and outlines the evolution and major changes since the introduction of TNF in ILP...
  57. ncbi Is the clinical risk score for patients with colorectal liver metastases still useable in the era of effective neoadjuvant chemotherapy?
    Ninos Ayez
    Division of Surgical Oncology, Erasmus University MC, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Ann Surg Oncol 18:2757-63. 2011
    ..Therefore, this study evaluates the predictive value of these CRSs in this specific group...
  58. ncbi Histamine combined with melphalan in isolated limb perfusion for the treatment of locally advanced soft tissue sarcomas: preclinical studies in rats
    Flavia Brunstein
    Laboratory of Experimental Surgical Oncology, Daniel den Hoed Cancer Center, Erasmus MC, Rotterdam, The Netherlands
    Acta Cir Bras 20:275-9. 2005
    ....
  59. ncbi Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis
    Amir Mearadji
    Department of Surgical Oncology, Erasmus Medical Center, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Anticancer Drugs 19:607-12. 2008
    ..For patients with metastatic GIST, the role of surgery remains less clear. Loss or decrease of CD117 expression in the resected specimen after imatinib treatment may be associated with disease recurrence...
  60. ncbi Tumor vascular therapy with TNF: critical review on animal models
    Timo L M ten Hagen
    Department of Surgical Oncology, Erasmus, The Netherlands
    Methods Mol Med 98:227-46. 2004
    ..In this chapter we will describe the use of specific animal models for efficacy studies, such as isolated limb perfusion and isolated liver perfusion in the rat...
  61. ncbi Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: a multicenter study in 388 patients with positive sentinel nodes
    Alexander C J van Akkooi
    Department of Surgical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Ann Surg 248:949-55. 2008
    ..This is characterized by an increased detection of cases with minimal tumor burden (SUB-micrometastasis <0.1 mm), which represents different biology...
  62. ncbi Serum amino acids, biopterin and neopterin during long-term immunotherapy with interferon-alpha in high-risk melanoma patients
    Arthur R Van Gool
    Department of Psychosocial Oncology, Erasmus Medical Center Daniel den Hoed Cancer Center, P O Box 5201, 3008 AE, Rotterdam, The Netherlands
    Psychiatry Res 119:125-32. 2003
    ..Changes in tryptophan metabolism may play a role in the pathophysiology of the neuropsychiatric side effects of IFN-alpha, and further research into the predictive potential of NEOP is warranted...
  63. ncbi Importance of tumor load in the sentinel node in melanoma: clinical dilemmas
    Alexander C J van Akkooi
    Department of Surgical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, Groene Hilledijk 301, Kamer A1 41, 3075 EA Rotterdam, The Netherlands
    Nat Rev Clin Oncol 7:446-54. 2010
    ..1 mm by the Rotterdam Criteria have excellent survival rates. Ultrasound-guided fine-needle aspiration cytology is emerging as a staging tool for high-risk patients, but more research is necessary before this can change clinical practice...
  64. ncbi Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon
    Marna G Bouwhuis
    Department of Surgical Oncology, Erasmus University MC Daniel den Hoed Cancer Center, 301 Groene Hilledijk, Rotterdam, The Netherlands
    J Natl Cancer Inst 101:869-77. 2009
    ....
  65. ncbi Local treatment for recurrent colorectal hepatic metastases after partial hepatectomy
    Anne E M van der Pool
    Department of Surgical Oncology, Erasmus University MC Daniel den Hoed Cancer Center, PO Box 5201, 3008, Rotterdam, AE, The Netherlands
    J Gastrointest Surg 13:890-5. 2009
    ..The objective of the study was to identify patients who may benefit from local treatment in recurrent colorectal liver metastases...
  66. ncbi Isolated hypoxic hepatic perfusion with orthograde or retrograde flow in patients with irresectable liver metastases using percutaneous balloon catheter techniques: a phase I and II study
    Boudewijn van Etten
    Department of Surgical Oncology, Erasmus University Medical Center-Daniel den Hoed Cancer Center, PO Box 5201, 3008 AE Rotterdam, The Netherlands
    Ann Surg Oncol 11:598-605. 2004
    ..We are presently conducting a study using a simplified surgical retrograde IHHP method, in which leakage is fully controlled, which translates into high response rates...
  67. ncbi Preoperative radiotherapy improves outcome in recurrent rectal cancer
    Maarten Vermaas
    Department of Surgical Oncology, Erasmus MC-Daniel den Hoed Cancer Center, 3008 Rotterdam, The Netherlands
    Dis Colon Rectum 48:918-28. 2005
    ..Preoperative radiotherapy should be standard treatment for patients with recurrent rectal cancer...
  68. ncbi EORTC Melanoma Group sentinel node protocol identifies high rate of submicrometastases according to Rotterdam Criteria
    Augustinus P T van der Ploeg
    Department of Surgical Oncology, Erasmus University Medical Center, The Netherlands
    Eur J Cancer 46:2414-21. 2010
    ..1 mm) had a 5 year OS rate of 91%, virtually identical to 90% for SN-negative patients. The NSN positivity rate of 0% in these patients indicates that they may be spared a completion lymph node dissection (CLND) and its morbidity...
  69. ncbi Pegylated liposomal tumor necrosis factor-alpha results in reduced toxicity and synergistic antitumor activity after systemic administration in combination with liposomal doxorubicin (Doxil) in soft tissue sarcoma-bearing rats
    Timo L M ten Hagen
    Department of Surgical Oncology, University Hospital Rotterdam Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Int J Cancer 97:115-20. 2002
    ..These results indicate that pegylated liposomal encapsulation may be effective in systemic application of TNF for combined treatment with liposomal chemotherapy of advanced solid tumors...
  70. ncbi European approach to the treatment of malignant melanoma
    Alexander M M Eggermont
    Department of Surgical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Curr Opin Oncol 14:205-11. 2002
    ..In Europe biochemotherapy is being abandoned and various less toxic or nontoxic approaches with vaccines and antiangiogenic agents are under study...
  71. ncbi Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma
    Wim H J Kruit
    Erasmus Medical Center-Daniel den Hoed Cancer Center, Department of Internal Oncology, Rotterdam, The Netherlands
    Int J Cancer 117:596-604. 2005
    ....
  72. ncbi Lack of cell-cycle specific effects of tumor necrosis factor-alpha on tumor cells in vitro: implications for combination tumor therapy with doxorubicin
    Alexander H van der Veen
    Laboratory for Experimental Surgical Oncology, Room Ee 0102a, Department of Surgical Oncology, University Hospital Rotterdam-Dijkzigt/Daniel Den Hoed Cancer Center, Erasmus University, P.O. Box 1738, 3000 DR Rotterdam, The Netherlands
    Cancer Invest 20:499-508. 2002
    ..Only the tested rat osteosarcoma tumor cells demonstrated a cell arrest in the G2 phase, which did not result in attenuation of the cytotoxicity of doxorubicin towards these cells...
  73. ncbi Fifty tumor necrosis factor-based isolated limb perfusions for limb salvage in patients older than 75 years with limb-threatening soft tissue sarcomas and other extremity tumors
    Boudewijn van Etten
    Department of Surgical Oncology, University Hospital Rotterdam-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Ann Surg Oncol 10:32-7. 2003
    ..CONCLUSIONS: Older patients should not be withheld a TNF-based ILP for limb salvage, because the procedure is safe and highly effective in these patients...
  74. ncbi Endothelial monocyte-activating polypeptide-II and its functions in (patho)physiological processes
    Remco van Horssen
    Laboratory of Experimental Surgical Oncology, Department of Surgical Oncology, Erasmus University MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Cytokine Growth Factor Rev 17:339-48. 2006
    ..We also discuss the different reported mechanisms for processing of proEMAP/p43 into EMAP-II. Finally, we speculate on the possible applications of this cytokine for (cancer) therapy...
  75. ncbi Hyperthermia and thermosensitive liposomes for improved delivery of chemotherapeutic drugs to solid tumors
    Gerben A Koning
    Laboratory Experimental Surgical Oncology, Section Surgical Oncology Department of Surgery, Erasmus Medical Center, Rotterdam, PO Box 2040, 3000, CA, Rotterdam, The Netherlands
    Pharm Res 27:1750-4. 2010
    ..By applying these two strategies, drug delivery to tumors can be strongly enhanced...
  76. ncbi Immunostimulation versus immunosuppression after multiple vaccinations: the woes of therapeutic vaccine development
    Alexander M M Eggermont
    Erasmus University Medical Center, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Clin Cancer Res 15:6745-7. 2009
    ..Modulation of regulatory T-cell activity may be required to overcome this outcome and may be crucial for the successful development of therapeutic vaccines...
  77. ncbi Enriching lipid nanovesicles with short-chain glucosylceramide improves doxorubicin delivery and efficacy in solid tumors
    Menno van Lummel
    Department of Cellular Biochemistry, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    FASEB J 25:280-9. 2011
    ..This new drug delivery concept, aiming at increased membrane permeability for amphiphilic drugs, provides an opportunity to improve cancer chemotherapy...
  78. ncbi Mastectomy by inverted drip incision and immediate reconstruction: data from 510 cases
    Albert N Van Geel
    Department of Surgical Oncology, Erasmus Medical Center Daniel den Hoed Cancer Clinic, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
    Ann Surg Oncol 10:389-95. 2003
    ..Despite the frequency with which these procedures are performed, data from large series of subpectoral implantation of silicone prostheses in combination with a skin-saving approach are lacking...
  79. ncbi Changes of ferritin and CRP levels in melanoma patients treated with adjuvant interferon-α (EORTC 18952) and prognostic value on treatment outcome
    Marna G Bouwhuis
    Laboratory Experimental Surgical Oncology, Section Surgical Oncology, Department of Surgery, Erasmus MC, Rotterdam 3015 GE, The Netherlands
    Melanoma Res 21:344-51. 2011
    ..Administration of IFN in melanoma patients induced increase in ferritin levels but not in CRP levels. Ferritin and CRP ratios have no prognostic value regarding DMFS...
  80. ncbi Changing the pathophysiology of solid tumours: the potential of TNF and other vasoactive agents
    Timo L M ten Hagen
    Department of Surgical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Int J Hyperthermia 22:241-6. 2006
    ..Here some of the methodologies and drug combinations which improve solid tumour therapy through acting on the tumour pathophysiology are discussed...
  81. ncbi Critical appraisal of IFN-alpha-based adjuvant therapy in stage II-III malignant melanoma
    Alexander M M Eggermont
    Department of Surgical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, 301 Groene Hilledijk, 3075 EA Rotterdam, The Netherlands
    Expert Rev Anticancer Ther 2:563-9. 2002
    ..Since the impact of dose and duration of treatment also awaits further evaluation. It is reasonable to state that the role of interferon in melanoma still remains to be defined...
  82. ncbi Polymorphisms in the CD28/CTLA4/ICOS genes: role in malignant melanoma susceptibility and prognosis?
    Marna G Bouwhuis
    Erasmus Medical Center Daniel den Hoed Cancer Center, Dr Molewaterplein 50, 3015 GE Rotterdam, The Netherlands
    Cancer Immunol Immunother 59:303-12. 2010
    ....
  83. ncbi Immunotherapy: Vaccine trials in melanoma -- time for reflection
    Alexander M M Eggermont
    Department of Surgical Oncology, Daniel den Hoed Cancer Center, Erasmus University MC, Rotterdam, The Netherlands
    Nat Rev Clin Oncol 6:256-8. 2009
    ....
  84. ncbi Isolated hepatic perfusion: experimental evidence and clinical utility
    Johannes H W de Wilt
    Erasmus MC (University Medical Center Rotterdam)-Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
    Surg Clin North Am 84:627-41. 2004
    ..Future research should be directed to the identification of suitable biological or chemotherapeutic agents, defining clinical indications, and development of technical modifications to make it more generally applicable...
  85. ncbi Detection of melanoma micrometastases in sentinel nodes - the cons
    Johannes H W de Wilt
    Department of Surgical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, P O Box 5201, 301 Groene Hilledijk, 3008 AE, Rotterdam, The Netherlands
    Surg Oncol 17:175-81. 2008
    ..Patients with this limited tumor burden in their SN have an excellent prognosis and are highly unlikely to benefit from CLND. New techniques such as ultrasound of the lymph nodal basin can be promising as an alternative for SN biopsy...
  86. ncbi Hereditary breast cancer growth rates and its impact on screening policy
    Madeleine M A Tilanus-Linthorst
    Department of Surgical Oncology, Erasmus University Medical Centre, Rotterdam, The Netherlands
    Eur J Cancer 41:1610-7. 2005
    ..It is recommended that the screening frequency should be adjusted according to a woman's age and a high-sensitive biannual test may be appropriate before the age of 40 years...
  87. ncbi Prognosis of primary mucosal penile melanoma: a series of 19 Dutch patients and 47 patients from the literature
    Albertus N van Geel
    Department of Surgical Oncology, Erasmus Medical Center, Rotterdam, The Netherlands
    Urology 70:143-7. 2007
    ..To analyze the clinical features, prognostic factors, and survival of male patients with primary mucosal melanoma on the glans penis, meatus, fossa navicularis, and distal urethra...
  88. ncbi Therapeutic vaccines in solid tumours: can they be harmful?
    Alexander M M Eggermont
    Department of Surgical Oncology, Erasmus University MC, Daniel den Hoed Cancer Center, 301 Groene Hilledijk, 3075 EA Rotterdam, The Netherlands
    Eur J Cancer 45:2087-90. 2009
    ....
  89. ncbi Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study
    Sandra L Wong
    Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    Ann Surg Oncol 13:809-16. 2006
    ..CONCLUSIONS: This study underscores the importance of ongoing prospective randomized trials in determining the therapeutic value of CLND after positive SLN biopsy in melanoma patients...
  90. ncbi TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility
    Remco van Horssen
    Department of Surgical Oncology, Erasmus MC--Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Oncologist 11:397-408. 2006
    ..In addition, possible factors modulating TNF-alpha actions are discussed...
  91. ncbi Reducing the need for sentinel node procedures by ultrasound examination of regional lymph nodes
    Alexander M M Eggermont
    Ann Surg Oncol 12:3-5. 2005
  92. ncbi Gene expression profiling of primary cutaneous melanoma and clinical outcome
    Veronique Winnepenninckx
    Department of Pathology, Gustave Roussy Institute, 94805 Villejuif Cedex, France
    J Natl Cancer Inst 98:472-82. 2006
    ..To identify differentially expressed genes that may be involved in melanoma progression and prognosis, we investigated the relationship between gene expression profiles and clinical outcome in a cohort of patients with primary melanoma...
  93. ncbi Isolated limb perfusion prolongs the limb recurrence-free interval after several episodes of excisional surgery for locoregional recurrent melanoma
    Eva M Noorda
    Department of Surgery, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Ann Surg Oncol 11:491-9. 2004
    ..Therefore, ILP could be a valuable adjunct to excisional surgery for in-transit metastases in these patients whose LRFIs tend to shorten over time...
  94. ncbi Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial
    Henrik Schmidt
    Department of Oncology, Aarhus University Hospital, Aarhus C, Denmark
    J Clin Oncol 25:1562-9. 2007
    ..In this study, we aimed to validate this finding in a large cohort of stage IV melanoma patients...
  95. ncbi Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group
    Ulrich Keilholz
    Department of Medicine III, Charite, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
    J Clin Oncol 23:6747-55. 2005
    ..This study was performed to determine whether interleukin-2 (IL-2) as a component of chemoimmunotherapy influences survival of patients with metastatic melanoma...
  96. ncbi Hyperthermic isolated limb perfusion with tumor necrosis factor is a useful therapy for advanced melanoma of the limbs
    Ferdy J Lejeune
    J Clin Oncol 25:1449-50; author reply 1450-1. 2007
  97. ncbi The risk of in-transit melanoma metastasis depends on tumor biology and not the surgical approach to regional lymph nodes
    Timothy M Pawlik
    Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 23:4588-90. 2005
  98. ncbi Management of melanoma patients: benefit of intense follow-up schedule is not demonstrated
    Philippe Autier
    J Clin Oncol 21:3707; author reply 3707-8. 2003
  99. ncbi Reaching first base in the treatment of metastatic melanoma
    Alexander M M Eggermont
    J Clin Oncol 24:4673-4. 2006
  100. ncbi EMAP-II facilitates TNF-R1 apoptotic signalling in endothelial cells and induces TRADD mobilization
    Remco van Horssen
    Laboratory of Experimental Surgical Oncology, Department of Surgical Oncology, 3000 Daniel den Hoed Cancer Centre, Erasmus MC Room Ee 0104, PO Box 1738, Rotterdam, The Netherlands
    Apoptosis 11:2137-45. 2006
    ....
  101. ncbi The role of isolated limb perfusion for melanoma confined to the extremities
    Alexander M M Eggermont
    Department of Surgical Oncology, Erasmus University Medical Center, Rotterdam Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Surg Clin North Am 83:371-84, ix. 2003
    ..TNF changes the pathophysiology, greatly enhances the uptake of Melphalan and destructs selectively the vasculature of large tumors. To date, ILP is not indicated in an adjuvant setting...